Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 14, 2007

CEL-SCI Secures Manufacturing Facility for Cancer Drug

  • CEL-SCI entered into an agreement with a biomedical real estate group under which it acquires long-term use of a dedicated manufacturing plant near Baltimore for its cancer drug Multikine. The financial value of this transaction to CEL-SCI is about $15 million.

    BioRealty is responsible for its build-out pursuant to CEL-SCI's specifications. Once fully built, the facility will produce Multikine for its Phase III trials for head and neck cancer as well as other oncology indications, following marketing approval for sale. The company reports that this transaction allows it to preserve its cash as well as pursue the development of its cancer drug in the most prudent manner.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »